Chronic Diseases Prevention Review (Online ISSN: 2158-0820)

by Ling Yan Xiaofeng Yuan Donglin Zhu Mingliang Li

Chronic Diseases Prevention Review 2021 5(20)14-19; published online  21 October 2021

Abstract: To investigate the prognosis of antiviral therapy in chronic hepatitis B patients with HBsAg and anti-HBs co-existence. Methods: Electrochemiluminescence immunoassay (ECLIA) was used to screen patients with HBsAg and anti-HBs co-existence (experimental group) and HBsAg-positive patients (control group) in patients with chronic hepatitis B. The levels of serum HBV DNA load, AFP and hepatic function before and after the administration of the drug were measured, the effect of antiviral therapy and the prognosis of patients were analyzed compared. Results: There was no significant difference in the age, gender and other basic indicators between the experimental group and the control group (P>0.05). In the experimental group, after the antiviral treatment, the HBV DNA load, AFP, and liver function were improved compared with baseline characteristics, and the difference was statistically significant (P<0.05). In the experimental group and the control group, the differences in HBV DNA load, AFP, and liver function levels before and after antiviral treatment were statistically significant (P<0.05). Conclusions: Antiviral treatment of patients with co-existent HBsAg and anti-HBs in chronic hepatitis B patients as well as antiviral treatment in patients with HBsAg-positive chronic hepatitis B has significantly improved their prognosis, but the prognosis of the former is slightly worse than that of the latter, patients are more likely to develop cirrhosis and even liver cancer, which should attract laboratory and clinical attention.